EWTX (Edgewise Therapeutics) Construction In Progress: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EWTX Edgewise Therapeutics Inc EWTX
28 GF Score
Price $41.94
! 3 Warning Signs
View Full Analysis

What is Edgewise Therapeutics Construction In Progress?

Edgewise Therapeutics EWTX -0.10% 28 Construction In Progress is $0.00 Mil as of Jun. 2026. GuruFocus rates EWTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Edgewise Therapeutics's quarterly construction in progress declined from Dec. 2025 ($0.08 Mil) to Mar. 2026 ($0.00 Mil) but then stayed the same from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.00 Mil).

Edgewise Therapeutics's annual construction in progress declined from Dec. 2023 ($0.08 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.08 Mil).

Edgewise Therapeutics Construction In Progress Historical Data

* Premium members only.

The historical data trend for Edgewise Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edgewise Therapeutics Construction In Progress Chart

Edgewise Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial 0.00 7.34 0.08 0.00 0.08

Edgewise Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.08 0.00 0.00
EWTX
28GF Score
Edgewise Therapeutics Inc EWTX
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edgewise Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.00 Mil mean?
Edgewise Therapeutics (EWTX) has a Construction In Progress of $0.00 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Edgewise Therapeutics and its competitors.
Is Edgewise Therapeutics' Construction In Progress too high?
Edgewise Therapeutics' current Construction In Progress is $0.00 Mil. Overall, Edgewise Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Edgewise Therapeutics' Construction In Progress compare to DYN and PBLS?
Edgewise Therapeutics' Construction In Progress of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Edgewise Therapeutics and its competitors. Edgewise Therapeutics's current Construction In Progress is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edgewise Therapeutics stock overvalued right now?
Edgewise Therapeutics (EWTX) has a current Construction In Progress of $0.00 Mil. The current Construction In Progress is $0.00 Mil. Edgewise Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Edgewise Therapeutics (EWTX), the current Construction In Progress is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edgewise Therapeutics Business Description

Address 1715 38th Street, Boulder, CO, USA, 80301
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
28GF Score

Get the complete analysis for EWTX

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.94
Price